BioNTech is a biotechnology company based in Germany that specializes in developing individualized therapies for significant diseases, including cancer and infectious diseases. Founded in 2008, the company gained widespread recognition for its role in developing one of the first COVID-19 vaccines, in collaboration with Pfizer. BioNTech’s approach leverages messenger RNA (mRNA) technology to instruct cells to produce proteins that can trigger an immune response, thereby training the immune system to recognize and combat pathogens or tumor cells. The company’s focus encompasses a range of innovative treatments and vaccines, utilizing advanced science and technology to address unmet medical needs.
BioNTech, based in Mainz, is transitioning from a COVID-19 focus to pioneering cancer therapies, despite financial challenges. Fourth-quarter 2024 profits dropped, but results beat market expectations, highlighting resilience. The company…